Anti -cancer new drug research and development agent Tajiri Biocence of several hundred million yuan B financing

On July 5th, Capital State learned that according to IT orange, Tagiri Bio recently announced the completion of hundreds of millions of yuan B financing, and the investor has not disclosed it yet.

The funds raised in this round of financing will be mainly used to promote the development and further expansion of global innovation projects of TGRX-678 and TGRX-326, as well as the company's global innovation projects of other FIRST-In-Class, Best-IN-Class.

Tajiri Bio is a new anticancer drug research and developer that focuses on the treatment of scientific research, development, sales and services for cancer treatment of small molecules targeting innovative drugs.CDK4/6 oral inhibitors, chronic granulocyte leukemia BCR-ABL inhibitors, etc.

- END -